我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

依折麦布联合辛伐他汀对冠心病患者的调脂作用(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2012年第3期
页码:
388-390
栏目:
临床研究
出版日期:
2012-06-25

文章信息/Info

Title:
Lipid regulation using ezetimibe combined with simvastatin in patients with coronary heart disease
作者:
辛 倩; 单兆亮
(解放军总医院心内科，北京 100853)
Author(s):
XIN Qian;  SHAN Zhao-liang
(Department of Cardiology, PLA General Hospital, Beijing 100853, China)
关键词:
依折麦布; 辛伐他汀; 血脂; 冠状动脉疾病
Keywords:
ezetimibe;  simvastatin;  coronary artery disease
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的:探讨依折麦布联合辛伐他汀对冠心病患者血脂及炎性因子的调节作用。方法： 选取2011年5月~9月我院收治的冠心病患者60例，随机分为试药组和对照组，每组各30例，试药组采用依折麦布(10 mg/d)联合辛伐他汀(20 mg/d)，对照组单独使用辛伐他汀（40 mg/d）。在服药前、用药4周、用药8周时分别测定总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、肝功能、肾功能、肌酸激酶(CK)。结果： 与用药前基线水平相比，两组用药4周TC、LDL-C水平均显著下降（P<0.05），治疗8周均进一步下降（P<0.01），并且与对照组相比，试药组8周TC、LDL-C下降水平更显著（P<0.05）。两组患者的肝功能、肾功能、CK在用药后均无明显异常。结论： 依折麦布联合辛伐他汀能更有效地降低冠心病患者血脂水平。
Abstract:
AIM:To explore the regulatory effect of ezetimibe combined with simvastatin on lipid and inflammatory cytokines in patients with coronary heart disease (CHD). METHODS: Sixty patients with CHD admitted to our hospital between May 2011 and September 2011 were randomly divided into two groups: treatment group and control group (30 patients/group). Ezetimibe (10 mg/day) combined with simvastatin (20 mg/day) was used in the treatment group and independent simvastatin (40 mg/day) was administered in the control group. Total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), hepatic function, renal function, and creatine kinase (CK) were examined, respectively, before administration and 4 weeks and 8 weeks after administration. RESULTS: Compared with baseline level, TC and LDL-C decreased in the two groups 4 weeks after administration (P<0.05). After 8 weeks, these indicators decreased further in both groups (P<0.01). Compared with those in control group, TC and LDL-C in treatment group significantly decreased after 8 weeks (P<0.05). No significant differences of hepatic function, renal function and CK were found in both groups. CONCLUSION: Ezetimibe combined with simvastatin was shown to be more effective in decreasing serum lipid concentrations in patients with CHD.

参考文献/References

[1]赵水平.大幅度降低胆固醇能更有效地防治冠心病[J].中华心血管病学杂志,2005,33(12):1161-1163.

[2]Miura S,Saku K.Beneficial effects of ezetimibe-based therapy in patients with dyslipidemia[J].J Cardiol,2008,52(1):1-6.

[3]邹 燕,李 薇,王 强.他汀类药物在冠心病治疗中的应用[J].现代医药卫生,2011,27(6):874-875.

[4]白 元，秦永文.新型降脂药-依折麦布的研究进展[J]. 药学服务与研究,2007,7(3):187-190.

[5]朱 玮,杨向军.他汀类药物在冠心病治疗中的非调脂作用[J].苏州医学,2010,33(2):109-113.

[6]程妹娟,颜红兵,马 芹.联合应用依折麦布对他汀治疗冠心病患者血脂达标率的影响[J].中华流行病学杂志,2009,30(6):631-632.

[7]熊 祯，翟所迪，陈凤荣.新型血脂调节药-依折麦布[J].中国新药与临床杂志,2007,26(11):864-868.

备注/Memo

备注/Memo:
收稿日期：2012-01-11.通讯作者：单兆亮，主任医师，主要从事电生理学研究 Email:shanzl301@sina.com 作者简介：辛倩，硕士生 Email:iamcindy_1982@yahoo.com.cn
更新日期/Last Update: 2012-05-02